Samsung Medical Center: Breast Neoplasms trials

The registry lists 47 Breast Neoplasms studies with Samsung Medical Center as lead sponsor. 14 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 4Phase 4 1No phase 35(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Radiotherapy and Long-term Outcomes in Early Breast Cancer With SLNB OmissionRecruitingNCT07803081
• Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast CancerNot yet recruitingNCT07757958Phase 3
• This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer.Not yet recruitingNCT07309887
• Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer SurvivorsRecruitingNCT06729684Not applicable
• Brain Metastasis Development Mechanism in BCBM PatientsRecruitingNCT06330870Not applicable
• The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.RecruitingNCT06330012Not applicable
• LAG3 Expression in Triple Negative Breast CancerRecruitingNCT06259162Not applicable
• Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast CancerRecruitingNCT05933733
• Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerRecruitingNCT05910710
• Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)RecruitingNCT05907681
• Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast CancerRecruitingNCT05896865Not applicable
• Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast CancerRecruitingNCT05893966
• PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo StudyRecruitingNCT04819243Phase 2
• Effect of Prophylactic Medical Compression Therapy on the Reduction of Breast Cancer-related Lymphedema in Patients With Adjuvant Docetaxel Chemotherapy: a Randomized Controlled StudyRecruitingNCT04787029Not applicable
• Exosome as the Prognostic and Predictive Biomarker in EBC PatientsActive, not recruitingNCT05955521Not applicable
• Comparison of Ultrasound and Breast MRI for Breast Cancer DetectionActive, not recruitingNCT05797545Not applicable
• Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast CancerCompletedNCT04781712Not applicable
• Cooling Cap Trial to Prevent Permanent Chemotherapy-induced Alopecia in Breast Cancer PatientsCompletedNCT04678544Not applicable
• ABUS for Early-stage Breast CancerStatus unknownNCT04607473Not applicable
• Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast CancerStatus unknownNCT04429633Not applicable
• Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic MutationStatus unknownNCT04368442
• Real-time Interactive Digital Healthcare System in Patients With Breast Cancer; Randomized Controlled TrialCompletedNCT04316156Not applicable
• Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP ChemotherapyStatus unknownNCT04276337
• Genetic Characteristics of Metastatic Breast Cancer PatientsStatus unknownNCT04258735Not applicable
• High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)Status unknownNCT04247633Phase 2
• T-DM1 in HER2-positive Metastatic/Relapsed Breast CancerStatus unknownNCT04202328
• Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things DeviceStatus unknownNCT04116827
• TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After SurgeryStatus unknownNCT03881878Phase 1/2
• The Effects of Anesthetics on Persistent Pain Following Breast Cancer SurgeryCompletedNCT03782896
• Capsule Biopsy in Acellular Dermal Matrix-based Prosthetic Breast Reconstruction: a Prospective Pilot StudyCompletedNCT03744273Not applicable
• Early Rehabilitation After Immediate Reconstruction With TEI in Breast Cancer PatientsCompletedNCT03541161
• The Resistance and Immune Response to Palbociclib in Breast CancerStatus unknownNCT03401359Not applicable
• Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast CancerActive, not recruitingNCT03269981Not applicable
• Young Breast Cancer Cohort StudyStatus unknownNCT03131089
• Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast CancerStatus unknownNCT02967146Phase 3
• Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast CancerStatus unknownNCT02781259Phase 4
• A Trial of Evonail® Solution for Prevention or Treatment of OnycholysisCompletedNCT02670603Not applicable
• Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast CancerStatus unknownNCT02597179
• A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCStatus unknownNCT02592746Phase 2
• Genetic Alteration After Systemic Treatment in Breast CancerStatus unknownNCT02591966
• A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR PathwayCompletedNCT02544997Phase 2
• Whole Breast RT on Prone Position in Korean WomenStatus unknownNCT02231112Phase 2
• Perioperative Inflammation and Breast Cancer OutcomeStatus unknownNCT02141139Phase 3
• Prognostic Relevance of Biological Subtype in Breast CancerStatus unknownNCT02063906
• Usefulness of Ki67 Index in Hormone Receptor-positive Breast CancerCompletedNCT01273415
• Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenStatus unknownNCT01266213Phase 2
• Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast CancerCompletedNCT00561119Phase 3